Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018

Sunnyvale, California (ots/PRNewswire) -

Building on its heritage of patient-first innovation, at this
year's ASTRO (American Society for Radiation Oncology) Annual
Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation
therapy solutions designed to enable clinicians to deliver truly
personalized cancer treatments aligned to the needs of each patient.
Meeting attendees can visit Accuray at booth #2511 on October 21 -
23, 2018 in San Antonio, Texas to learn how advances in Accuray
radiation therapy delivery systems and software are making it easier
and faster to provide extremely precise results for the full range of
cancer cases, from initial treatment to adaptive therapy to
retreatments.

(Logo:
https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg
)

"We are proud to have the opportunity to attend this important
meeting and provide access to information, demonstrations and
educational opportunities for learning about advances in Accuray
technologies. We are committed to partnering with the radiation
oncology community to develop innovative products that will improve
patient care, now and into the future," said Lionel Hadjadjeba, M.D.,
Senior Vice President, and Chief Commercial Officer at Accuray.

Meeting Highlights

New products and upcoming developments

- CyberKnife® VOLO(TM) Optimizer: This next-generation optimizer
simplifies the process of creating treatment plans, improves plan
quality and enables more efficient exploration of the tradeoffs
between treatment time and plan quality. Preliminary data from
Accuray indicates that the CyberKnife VOLO Optimizer will provide a
significant reduction in optimization time, and up to 50 percent
reduction in treatment delivery time. Accuray will be launching
this new optimizer at its booth at 11:00 am on Sunday, October 21st
- CTrue(TM) IR (Iterative Reconstruction) for the Radixact® System:
This powerful IR software improves soft-tissue contrast and reduces
noise, enhancing image quality, while maintaining the same low
imaging dose and fast reconstruction time as earlier versions of
the software. These enhancements enable clinicians to efficiently
deliver precise treatments more quickly, for more patients.
- Radixact System with Real-Time Motion Synchronization* [510(k)
pending, not available for sale]: Capabilities of the Radixact
System are being expanded to offer real-time motion
synchronization, with the goal of improving dose accuracy and
treatment times compared to other methods, such as gating. These
capabilities will build on the current Radixact System, which is
fully integrated with the Accuray Precision® Treatment Planning
System and iDMS(TM) Data Management System. These hardware and
software solutions work seamlessly together and were introduced to
help improve treatment outcomes and workflow efficiencies, enabling
clinicians to provide optimal treatments for more patients, every
day. *Not 510(k) cleared or available for commercial distribution

Events

Accuray will host two educational symposia and a broad range of
Accuray Exchange in Radiation Oncology (AERO(TM)) Academy sessions.
ASTRO meeting attendees will have the chance to learn from industry
experts about clinical advances and best practices that have the
potential to improve cancer patients' outcomes and quality of life.

Click here (https://accurayexchange.com/news-events/events/09-07-2
018/astro-accuray-symposium-2018) for more information or to register
for the symposia.

Symposia: Breast Cancer: Your Challenges Today - Our Solutions
for Tomorrow:

Sunday, October 21st from 12:15p.m. - 1:15p.m.

- Moderator: Jean-Philippe Pignol, M.D., Ph.D. FRCPC; Dalhousie
University, Halifax, Canada
- Panelists - Asal Shoushtari Rahimi, M.D., MS; U.T. Southwestern
Medical
Center, Dallas, TX, USA
- Nathan Corradini, MS, DABR SSRMP; Clinica Luganese, Lugano,
Switzerland
- Jennifer R. Bellon, M.D.; Dana-Farber Cancer Institute, Boston,
MA, USA
- Carole Massabeau, M.D.; Institut Universitaire du Cancer de
Toulouse Oncopole, Toulouse, France

Symposia: Dynamic Tracking and Motion Correction: Over 15 Years
of Accuray Leadership:

Monday, October 22nd from 12:30p.m. - 1:30p.m.

- Moderator: Fabienne Hirigoyenberry-Lanson, P.hD., Vice President
Global Medical and Scientific Affairs, Accuray
- Panelists - Cristian Cotrutz, Ph.D.; Swedish Radiosurgery Center,
Seattle, WA,
USA
- Jonathan W. Lischalk, M.D.; Medstar Georgetown University
Hospital, Washington, DC, USA
- John Bayouth, Ph.D.; University of Wisconsin School of Medicine
and Public Health, Madison, WI, USA

AERO(TM) Academy Sessions: October 21st - October 23rd

Attendees at this year's ASTRO meeting will have the opportunity
to participate in interactive discussions with clinical experts on
the use of Accuray technologies during daily presentations at Accuray
booth #2511. Topics include building a CyberKnife® prostate SBRT
practice; benefits of TomoDirect(TM) for breast cancer; interactive
planning on the CyberKnife System with the new VOLO(TM) Optimizer;
demonstration of PreciseRTX(TM) Retreatment Option; and plan
adaptation with improved MVCT on the Radixact® System.

Unique Hologram Technology

Throughout the ASTRO meeting attendees will have the opportunity
to view viRTual-Where Art Meets Science, an immersive virtual reality
experience that provides an opportunity to see how Accuray
patient-first innovations are transforming what is possible for
cancer patients around the world.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation therapy
and radiosurgery treatments. For more information, please visit
http://www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.

Safe Harbor

Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to clinical applications, clinical results,
patient experiences and outcomes, the availability and effectiveness
of new product enhancements and releases, and Accuray's leadership
position in radiation oncology innovation and technologies. These
forward-looking statements involve risks and uncertainties. If any of
these risks or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products, including new product offerings; the
company's ability to develop new products or enhance existing
products to meet customers' needs; delays in the development or
release of new offerings; the company's limited long-term clinical
data supporting the safety and efficacy of its products for certain
users and such other risks identified under the heading "Risk
Factors" in the company's annual report on Form 10-K, filed with the
Securities and Exchange Commission (the "SEC") on August 24, 2018 and
as updated periodically with the company's other filings with the
SEC.

Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events. The
company assumes no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information,
except to the extent required by applicable securities laws.
Accordingly, investors should not put undue reliance on any
forward-looking statements.

ots Originaltext: Accuray
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Accuray
Sancie Nakarat
+33-6-81-36-84-34
snakarat@accuray.com

Original-Content von: Accuray, übermittelt durch news aktuell